Unterschied zwischen beta und blockers

Try the new Google Books

Check out the new look and enjoy easier access to your favorite features

Try the new Google Books

Check out the new look and enjoy easier access to your favorite features

Page 2

Try the new Google Books

Check out the new look and enjoy easier access to your favorite features

1. Heidenreich PAMK, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281(20):1927–36.

   CAS  PubMed  Article  Google Scholar 

2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.

   PubMed  Article  Google Scholar 

3. Task Force on the management of STseamiotESoC, Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619.

   Article  CAS  Google Scholar 

4. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269–324.

   CAS  PubMed  Article  Google Scholar 

5. Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med. 2003;97(10):1094–101.

   CAS  PubMed  Article  Google Scholar 

6. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.

   CAS  PubMed  Article  Google Scholar 

7. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1753465817750524.

   PubMed  PubMed Central  Article  Google Scholar 

8. Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev 2018;27(149).

9. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;4:CD003566.

   Google Scholar 

10. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS ONE. 2014;9(11):e113048.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

11. Etminan MJS, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12(1):48.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

12. Dransfield MT, Voelker H, Bhatt SP, Brenner K, Casaburi R, Come CE, et al. Metoprolol for the Prevention of Acute Exacerbations of COPD. N Engl J Med. 2019;381(24):2304–14.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

13. Gulea C, Zakeri R, Quint JK. Effect of beta-blocker therapy on clinical outcomes, safety, health-related quality of life and functional capacity in patients with chronic obstructive pulmonary disease (COPD): a protocol for a systematic literature review and meta-analysis with multiple treatment comparison. BMJ Open. 2018;8(11):e024736.

    PubMed  PubMed Central  Article  Google Scholar 

14. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.

    PubMed  PubMed Central  Article  Google Scholar 

15. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

    PubMed  PubMed Central  Google Scholar 

16. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.

    PubMed  Article  Google Scholar 

17. Higgins JPTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions. New Jersey: Wiley; 2019.

    Google Scholar 

18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

    Article  Google Scholar 

19. van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Res Synth Methods. 2012;3(4):285–99.

    PubMed  Article  Google Scholar 

20. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PloS one. 2014;3;9(7):e99682.

21. Trinquart L, Attiche N, Bafeta A, Porcher R, Ravaud P. Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials. Ann Intern Med. 2016;164(10):666–73.

    PubMed  Article  Google Scholar 

22. Furukawa TA, Salanti G, Atkinson LZ, Leucht S, Ruhe HG, Turner EH, et al. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open. 2016;6(7):e010919.

    PubMed  PubMed Central  Article  Google Scholar 

23. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.

    Article  Google Scholar 

24. Bhatt SP, Wells JM, Kinney GL, Washko GR Jr, Budoff M, Kim YI, et al. Beta-blockers are associated with a reduction in COPD exacerbations. Thorax. 2016;71(1):8–14.

    PubMed  Article  Google Scholar 

25. Coiro S, Girerd N, Rossignol P, Ferreira JP, Maggioni A, Pitt B, et al. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail. 2017;19(2):271–9.

    CAS  PubMed  Article  Google Scholar 

26. Ekstrom MP, Hermansson AB, Strom KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):715–20.

    PubMed  Article  Google Scholar 

27. Gottlieb SSMR, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339(8):489–97.

    CAS  PubMed  Article  Google Scholar 

28. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009;11(3):292–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

29. Kubota Y, Asai K, Furuse E, Nakamura S, Murai K, Tsukada YT, et al. Impact of beta-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:515–23.

    PubMed  PubMed Central  Article  Google Scholar 

30. Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O’Connor CM. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol. 2013;111(4):582–7.

    CAS  PubMed  Article  Google Scholar 

31. Quint JK, Herrett E, Bhaskaran K, Timmis A, Hemingway H, Wedzicha JA, et al. Effect of beta blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ. 2013;347:f6650.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

32. Rodriguez-Manero M, Lopez-Pardo E, Cordero A, Ruano-Ravina A, Novo-Platas J, Pereira-Vazquez M, et al. A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population. Int J Chron Obstruct Pulmon Dis. 2019;14:371–80.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

33. Rutten FH, Hak Eelko ZNPA, Grobbee DE, Hoes AW. Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880–7.

    PubMed  Article  Google Scholar 

34. Scrutinio D, Guida P, Passantino A, Ammirati E, Oliva F, Lagioia R, et al. Acutely decompensated heart failure with chronic obstructive pulmonary disease: clinical characteristics and long-term survival. Eur J Intern Med. 2019;60:31–8.

    PubMed  Article  Google Scholar 

35. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.

    PubMed  PubMed Central  Article  Google Scholar 

36. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med. 2002;113(8):650–6.

    CAS  PubMed  Article  Google Scholar 

37. Staszewsky L, Cortesi L, Tettamanti M, Dal Bo GA, Fortino I, Bortolotti A, et al. Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009. Eur J Heart Fail. 2016;18(7):840–8.

    CAS  PubMed  Article  Google Scholar 

38. Su TH, Chang SH, Kuo CF, Liu PH, Chan YL. beta-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide population-based observational study. PLoS ONE. 2019;14(3):e0213187.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

39. Su VY, Chang YS, Hu YW, Hung MH, Ou SM, Lee FY, et al. Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease. Medicine (Baltimore). 2016;95(5):e2427.

    CAS  PubMed Central  Article  PubMed  Google Scholar 

40. Su VYYY, Perng DW, Tsai YH, Chou KT, Su KC, Su WJ, Chen PC, Yang KY. Real-world effectiveness of medications on survival in patients with COPD-heart failure overlap. Aging. 2019;11(11):3650.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

41. van Gestel YR, Hoeks SE, Sin DD, Welten GM, Schouten O, Witteveen HJ, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008;178(7):695–700.

    PubMed  Article  Google Scholar 

42. van Gestel YR, Hoeks SE, Sin DD, Stam H, Mertens FW, Bax JJ, van Domburg RT, Poldermans D. Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD. Int J Chronic Obstructive Pulm Dis. 2009;4:177.

    Google Scholar 

43. Wang WH, Cheng CC, Mar GY, Wei KC, Huang WC, Liu CP. Improving outcomes in chronic obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a nationwide observational study. Heart Vessels. 2019;34(7):1158–67.

    PubMed  Article  Google Scholar 

44. Zeng LH, Hu YX, Liu L, Zhang M, Cui H. Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clin Interv Aging. 2013;8:1157–65.

    CAS  PubMed  PubMed Central  Google Scholar 

45. Maltais F, Buhl R, Koch A, Amatto VC, Reid J, Gronke L, et al. Beta-blockers in COPD: a cohort study from the TONADO Research Program. Chest. 2018;153(6):1315–25.

    PubMed  Article  Google Scholar 

46. Rasmussen DB, Bodtger U, Lamberts M, Torp-Pedersen C, Gislason G, Lange P, et al. Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study. Thorax. 2020;75(11):928–33.

    PubMed  Article  Google Scholar 

47. Brooks TW, Creekmore F, Young DC, Asche CV, Oberg B, Samuelson WM. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking β-blockers. Pharmacotherapy. 2007;27(5):684–90.

    PubMed  Article  Google Scholar 

48. Farland MZ, Peters CJ, Williams JD, Bielak KM, Heidel RE, Ray SM. beta-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother. 2013;47(5):651–6.

    PubMed  Article  CAS  Google Scholar 

49. Sessa M, Mascolo A, Mortensen RN, Andersen MP, Rosano GMC, Capuano A, et al. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. Eur J Heart Fail. 2018;20(3):548–56.

    CAS  PubMed  Article  Google Scholar 

50. Adam WR, Meagher EJ, Barter CE. Labetalol, beta blockers, and acute deterioration of chronic airway obstruction. Clin Exp Hypertens A. 1982;4(8):1419–28.

    CAS  PubMed  Google Scholar 

51. Chang CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J. 2010;40(3):193–200.

    CAS  PubMed  Article  Google Scholar 

52. Chester EH, Schwartz HJ, Fleming GM. Adverse effect of propranolol on airway function in nonasthmatic chronic obstructive lung disease. Chest. 1981;79(5):540–4.

    CAS  PubMed  Article  Google Scholar 

53. Sinclair DJ. Comparison of effects of propranolol and metoprolol on airways obstruction in chronic bronchitis. Br Med J. 1979;1(6157):168.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

54. Dorow PBH, Tönnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol. 1986;31(2):143–7.

    CAS  PubMed  Article  Google Scholar 

55. Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009;11(7):684–90.

    CAS  PubMed  Article  Google Scholar 

56. Jabbal S, Anderson W, Short P, Morrison A, Manoharan A, Lipworth BJ. Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD. QJM. 2017;110(12):785–92.

    CAS  PubMed  Article  Google Scholar 

57. Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med. 2011;105:S44–9.

    PubMed  Article  Google Scholar 

58. Mainguy V, Girard D, Maltais F, Saey D, Milot J, Senechal M, et al. Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease. Am J Cardiol. 2012;110(2):258–63.

    CAS  PubMed  Article  Google Scholar 

59. McGavin CRWI. The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction. Br J Dis Chest. 1978;72:327–32.

    CAS  PubMed  Article  Google Scholar 

60. Ranchod SR. The effect of beta-blockers on ventilatory function in chronic bronchitis. South African Med J. 1982;61(12):423–4.

    CAS  Google Scholar 

61. van der Woude HJZJ, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers. Chest. 2005;127(3):818–24.

    PubMed  Article  Google Scholar 

62. Butland RJPJ, Geddes DM. Effect of beta-adrenergic blockade on hyperventilation and exercise tolerance in emphysema. J Appl Physiol. 1983;54(5):1368–73.

    CAS  PubMed  Article  Google Scholar 

63. Jabbal S, Lipworth BJ. Tolerability of bisoprolol on domiciliary spirometry in COPD. Lung. 2018;196(1):11–4.

    CAS  PubMed  Article  Google Scholar 

64. Ellingsen J, Johansson G, Larsson K, Lisspers K, Malinovschi A, Stallberg B, et al. Impact of comorbidities and commonly used drugs on mortality in COPD—Real-world data from a primary care setting. Int J Chron Obstruct Pulmon Dis. 2020;15:235–45.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

65. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245–57.

    CAS  PubMed  Article  Google Scholar 

66. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63(4):301–5.

    CAS  PubMed  Article  Google Scholar 

67. Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2020;41(46):4415–22.

    PubMed  PubMed Central  Article  Google Scholar 

68. Hjalmarson ÅHJ, Malek I, Ryden L, Vedin A, Waldenström A, Wedel H, Elmfeldt D, Holmberg S, Nyberg G, Swedberg K. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet. 1981;17(318):823–7.

    Article  Google Scholar 

69. Hjalmarson ÅGS, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA. 2000;283(10):1295–302.

    CAS  PubMed  Article  Google Scholar 

70. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1753465817750524.

    PubMed  PubMed Central  Article  Google Scholar 

71. Loth DW, Brusselle GG, Lahousse L, Hofman A, Leufkens HG, Stricker BH. beta-Adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study. Br J Clin Pharmacol. 2014;77(1):190–200.

    CAS  PubMed  Article  Google Scholar 

72. Oda N, Miyahara N, Ichikawa H, Tanimoto Y, Kajimoto K, Sakugawa M, et al. Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:1119–24.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Page 2

PRISMA